Hong Kong start-up tests gene-editing therapy for inherited eye diseases

A Hong Kong-based start-up, led by Professor Zheng Zongli, is testing a gene-editing therapy targeting inherited eye diseases at their genetic source. The therapy is in early development, with safety and accessibility as key hurdles. This represents a potential frontier in precision medicine but is far from clinical application.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works